Shares of Dipexium Pharmaceuticals Inc. (NASDAQ:DPRX) have received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.

Brokerages have set a 1-year consensus target price of $27.25 for the company and are anticipating that the company will post ($0.55) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Dipexium Pharmaceuticals an industry rank of 88 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research lowered Dipexium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 24th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/zacks-dipexium-pharmaceuticals-inc-nasdaqdprx-receives-average-recommendation-of-strong-buy-from-analysts.html

Dipexium Pharmaceuticals (NASDAQ:DPRX) traded down 1.9287% during trading on Wednesday, reaching $15.2599. The company had a trading volume of 21,598 shares. Dipexium Pharmaceuticals has a 12 month low of $6.04 and a 12 month high of $16.32. The stock has a 50 day moving average of $12.65 and a 200-day moving average of $10.79. The company’s market capitalization is $158.67 million.

Dipexium Pharmaceuticals (NASDAQ:DPRX) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.52) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.02. Equities research analysts expect that Dipexium Pharmaceuticals will post ($2.10) EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in DPRX. BlackRock Fund Advisors raised its stake in Dipexium Pharmaceuticals by 19.6% in the second quarter. BlackRock Fund Advisors now owns 15,674 shares of the company’s stock worth $155,000 after buying an additional 2,568 shares during the period. Renaissance Technologies LLC raised its stake in Dipexium Pharmaceuticals by 51.5% in the first quarter. Renaissance Technologies LLC now owns 25,900 shares of the company’s stock worth $246,000 after buying an additional 8,800 shares during the period. Raymond James & Associates acquired a new stake in Dipexium Pharmaceuticals during the second quarter worth about $312,000. Geode Capital Management LLC raised its stake in Dipexium Pharmaceuticals by 9.1% in the first quarter. Geode Capital Management LLC now owns 33,170 shares of the company’s stock worth $315,000 after buying an additional 2,759 shares during the period. Finally, Falcon Point Capital LLC raised its stake in Dipexium Pharmaceuticals by 12.5% in the second quarter. Falcon Point Capital LLC now owns 38,833 shares of the company’s stock worth $385,000 after buying an additional 4,315 shares during the period. 24.78% of the stock is currently owned by hedge funds and other institutional investors.

Dipexium Pharmaceuticals Company Profile

Dipexium Pharmaceuticals, Inc is a late-stage pharmaceutical company. The Company is focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a first-in-class, broad spectrum, topical antibiotic. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI).

5 Day Chart for NASDAQ:DPRX

Get a free copy of the Zacks research report on Dipexium Pharmaceuticals (DPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Dipexium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dipexium Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.